https://www.gellc.es/sobre-nosotros/publicaciones/ 2026-02-11T09:27:48+00:00 https://www.gellc.es/publication/biallelic-losses-of-13q-do-not-confer-a-poorer-outcome-in-chronic-lymphocytic-leukaemia-analysis-of-627-patients-with-isolated-13q-deletion/ 2026-02-11T09:22:46+00:00 https://www.gellc.es/publication/hairy-cell-leukemia-treated-initially-with-purine-analogs-a-retrospective-study-of-107-patients-from-the-spanish-cooperative-group-on-chronic-lymphocytic-leukemia-gellc/ 2026-02-11T09:23:07+00:00 https://www.gellc.es/publication/interstitial-13q14-deletions-detected-in-the-karyotype-and-translocations-with-concomitant-deletion-at-13q14-in-chronic-lymphocytic-leukemia-different-genetic-mechanisms-but-equivalent-poorer-clinica/ 2026-02-11T09:23:26+00:00 https://www.gellc.es/publication/a-high-proportion-of-cells-carrying-trisomy-12-is-associated-with-a-worse-outcome-in-patients-with-chronic-lymphocytic-leukemia/ 2026-02-11T09:23:44+00:00 https://www.gellc.es/publication/a-low-frequency-of-losses-in-11q-chromosome-is-associated-with-better-outcome-and-lower-rate-of-genomic-mutations-in-patients-with-chronic-lymphocytic-leukemia/ 2026-02-11T09:23:58+00:00 https://www.gellc.es/publication/the-addition-of-ofatumumab-to-the-conditioning-regimen-does-not-improve-the-outcome-of-patients-with-high-risk-cll-undergoing-reduced-intensity-allogeneic-haematopoietic-cell-transplantation-a-pilot/ 2026-02-11T09:24:20+00:00 https://www.gellc.es/publication/update-of-the-grupo-espanol-de-leucemia-linfocitica-cronica-clinical-guidelines-of-the-management-of-chronic-lymphocytic-leukemia/ 2026-02-11T09:24:45+00:00 https://www.gellc.es/publication/characterizing-patients-with-multiple-chromosomal-aberrations-detected-by-fish-in-chronic-lymphocytic-leukemia/ 2026-02-11T09:25:09+00:00 https://www.gellc.es/publication/clinical-outcome-and-prognostic-factors-of-patients-with-richter-syndrome-real-world-study-of-the-spanish-chronic-lymphocytic-leukemia-study-group-gellc/ 2026-02-11T09:25:59+00:00 https://www.gellc.es/publication/high-prognostic-value-of-measurable-residual-disease-detection-by-flow-cytometry-in-chronic-lymphocytic-leukemia-patients-treated-with-front-line-fludarabine-cyclophosphamide-and-rituximab-followed/ 2026-02-11T09:26:11+00:00 https://www.gellc.es/publication/clinical-characteristics-and-outcome-of-sars-cov-2-infection-in-admitted-patients-with-chronic-lymphocytic-leukemia-from-a-single-european-country/ 2026-02-11T09:26:37+00:00 https://www.gellc.es/publication/building-a-network-of-tp53-and-ighv-testing-reference-centers-across-spain-the-red53-initiative/ 2026-02-11T09:26:55+00:00 https://www.gellc.es/publication/ibrutinib-followed-by-ofatumumab-consolidation-in-previously-untreated-patients-with-chronic-lymphocytic-leukemia-cll-gellc-7-trial-from-the-spanish-group-of-cll-gellc/ 2026-02-11T09:27:30+00:00 https://www.gellc.es/publication/guidelines-for-the-diagnosis-and-treatment-of-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-from-chronic-lymphocytic-leukemia-spanish-group-gellc/ 2026-02-11T09:27:48+00:00